Enzalutamide
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Early Stage, Triple Negative Breast Cancer
Trial Timeline
May 19, 2016 → May 1, 2026
NCT ID
NCT02750358About Enzalutamide
Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02750358. Target conditions include Breast Cancer, Early Stage, Triple Negative Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Breast Cancer